¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Agonist maintenance treatment"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® agonist ÇÑ±Û ÀÛ¿ëÁ¦, ÀÛ¿ë±Ù
¼³¸í   
  1. ¼ö¿ëü¿Í °áÇÕÇÏ¿© ÃÖ´ëÀÇ ¾à¸®ÀÛ¿ëÀ» ¹ßÇöÇϴ ȭÇй°ÁúÀ» ¸»ÇÑ´Ù. ¼ö¿ëü¿¡ Æ¯ÀÌÇϰԠģȭ¼ºÀ» °¡Áö°í ÀÖ´Ù. »ýü ¾È¿¡¼­ »ý»êµÇ´Â ³»ÀμºÀΠ°Í°ú »ýü ¹Û¿¡¼­ Åõ¿©µÇ´Â ¿ÜÀμºÀΠ°ÍÀÌ ÀÖ´Ù. ºÎºÐ ÀÛ¿ëÁ¦´Â ¼ö¿ëü¿Í °áÇÕÇØµµ 100%ÀÇ ¾à¸®ÀÛ¿ëÀ» ¹ßÇöÇÏÁö´Â ¾ÊÀ¸¸ç ¿ë·®À» Áõ°¡½ÃÄѵµ È¿°ú´Â Ä¿ÁöÁö ¾Ê´Â´Ù. 2. ÇغÎÇп¡¼­´Â ÁÖ°¡ µÇ¾î ¿òÁ÷À̴ ±ÙÀ°ÀÇ ¹«¸®
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • health maintenance organization
    °Ç°­À¯Áö±â±¸
  • maintenance dose
    À¯Áö¿ë·®
  • maintenance heat
    À¯Áö¿­
  • maintenance hemodialysis
    Áö¼ÓÇ÷¾×Åõ¼®
  • maintenance solution
    À¯Áö¿ë¾×
  • agonist
    1. ÀÛ¿ëÁ¦ 2. ÀÛ¿ë±Ù
  • beta2-agonist
    º£Å¸2ÀÛ¿ëÁ¦
  • cholinergic agonist
    Äݸ°¼ºÀÛ¿ëÁ¦
  • dopamine agonist
    µµÆÄ¹ÎÀÛ¿ëÁ¦
  • GnRH agonist
    »ý½Ä»ùÀÚ±ØÈ£¸£¸ó¹æÃâÈ£¸£¸óÀÛ¿ëÁ¦
  • gonadotropin-releasing hormone agonist
    »ý½Ä»ùÀÚ±ØÈ£¸£¸ó¹æÃâÈ£¸£¸óÀÛ¿ëÁ¦
  • inverse agonist
    ¿ªÀÛ¿ëÁ¦
  • muscarinic agonist
    ¹«½ºÄ«¸°ÀÛ¿ëÁ¦
  • opioid agonist
    ¾ÆÆíÀ¯»çÀÛ¿ëÁ¦
  • active treatment
    Àû±ØÄ¡·á
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gonadotropin releasing hormone agonist agonist
    »ý½Ä»ùÀÚ±ØÈ£¸£¸óºÐºñÈ£¸£¸óÀÛ¿ëÁ¦
  • agonist
    1.ÀÛ¿ëÁ¦, 2.ÀÛ¿ë±Ù
  • beta2 agonist
    º£Å¸2ÀÛ¿ëÁ¦
  • dopamine agonist
    µµÆÄ¹ÎÀÛ¿ëÁ¦
  • GnRH agonist
    (¢¡gonadotropin releasing hormone agonist) »ý½Ä»ùÀÚ±ØÈ£¸£¸óºÐºñÈ£¸£¸óÀÛ¿ëÁ¦
  • self-treatment
    ÀÚ°¡Ä¡·á
  • treatment
    Ä¡·á, óġ
  • conservative treatment
    º¸Á¸Ä¡·á
  • dietetic treatment
    À½½ÄÄ¡·á
  • drug treatment
    ¾à¹°Ä¡·á
  • local treatment
    ±¹¼ÒÄ¡·á
  • mass treatment
    Áý´ÜÄ¡·á
  • occlusive treatment
    °¡¸²Ä¡·á
  • palliative treatment
    ¿ÏÈ­Ä¡·á, °í½ÄÄ¡·á
  • preventive treatment
    ¿¹¹æÄ¡·á
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • maintenance dose
    À¯Áö¿ë·®
  • maintenance heat
    À¯Áö¿­
  • maintenance hemodialysis
    Áö¼ÓÇ÷¾×Åõ¼®
  • maintenance solution
    À¯Áö¿ë¾×
  • agonist
    ÀÛ¿ëÁ¦, ÀÛ¿ë±Ù
  • cholinergic agonist
    Äݸ°¼ºÃËÁøÁ¦
  • inverse agonist
    ¿ªÀÛ¿ëÁ¦
  • muscarinic agonist
    ¹«½ºÄ«¸°ÀÛ¿ëÁ¦
  • opioid agonist
    ¾ÆÆíÀ¯»çÀÛ¿ëÁ¦
  • accelerated treatment
    °¡¼ÓÄ¡·á
  • active treatment
    Àû±ØÄ¡·á
  • aseptic treatment
    ¹«±ÕÄ¡·á
  • autoserum treatment
    ÀÚ°¡Ç÷ûġ·á
  • blanket mass treatment
    Àü¿øÄ¡·á
  • combination treatment
    º´¿ëÄ¡·á
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • GnRH agonist
    ¼º¼±ÀÚ±ØÈ£¸£¸ó À¯¸® È£¸£¸ó È¿´É¾à
  • alpha-adrenergic agonist
    ¾ËÆÄ¾Æµå·¹³¯¸°ÃËÁøÁ¦
  • Health Maintenance Organization
    °Ç°­À¯Áö±â±¸
  • health maintenance organizatiion(HMO)
    °Ç°­À¯ÁöÁ¶Á÷, ¹Ì±¹ÀÇ ÀǷẸÇè ÀÏÁ¾.
  • heat of maintenance
    À¯Áö¿­(ë«ò¥æð).
  • heat of maintenance
    À¯Áö¿­.
  • Calots treatment
    Ä®·Î¿ä¹ý.
  • Carrels treatment
    Ä«·¼¿ä¹ý.
  • Castellanis treatment
    Ä«½ºÅÚ¶ó´Ï¿ä¹ý.
  • Co-Tuis treatment
    ÄÚÅõÀÌ¿ä¹ý.
  • accelerated treatment
    °¡¼ÓÄ¡·á
  • acoustic treatment
    ÈíÀ½Ã³¸®
  • active treatment
    Á÷Á¢Ä¡·á, Àû±Ø¿ä¹ý(îÝпèþÛö).
  • antifat treatment
    Å»Áö¿ä¹ý(÷­ò·èþÛö).
  • antiseptic treatment
    ¹æºÎÀûóġ (¡­Àûóġ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adrenergic agonist
    ¾Æµå·¹³¯¸°¼ºÃËÁøÁ¦
  • agonist
    ÀÛ¿ëÁ¦(íÂéÄð¥), ÈïºÐÁ¦(ýéÝÇð¥)
  • agonist
    È¿´É¾à(üùÒöå·), È¿ÇöÁ¦(üùúéð¥).
  • alpha-adrenergic agonist
    ¾ËÆÄ¾Æµå·¹³¯¸°ÃËÁøÁ¦
  • cholinergic agonist
    Äݸ°¼º ÃËÁøÁ¦
  • dopamine agonist
    µµÆÄ¹Î È¿ÇöÁ¦(üùúÞð¥)
  • dopamine autoreceptor agonist
    µµÆÄ¹Î ÀÚ°¡¼ö¿ëü È¿ÇöÁ¦
  • inverse agonist
    ¿ª(¼º)È¿Çö<´É>Á¦.
  • muscarinic agonist
    ¹«½ºÄ«¸°¼ºÀÛ¿ëÁ¦
  • opioid agonist
    ¾ÆÆí¾çÀÛ¿ëÁ¦
  • partial agonist
    ºÎºÐÀû ÀÛ¿ë¾à(¡­íÂéÄå·).(¾à¸®)ºÎºÐ(Àû) È¿´É¾à, ºÎºÐ(Àû) È¿ÇöÁ¦.
  • health maintenance organizatiion(HMO)
    °Ç°­À¯ÁöÁ¶Á÷, ¹Ì±¹ÀÇ ÀǷẸÇè ÀÏÁ¾.
  • heat of maintenance
    À¯Áö¿­(ë«ò¥æð).
  • heat of maintenance
    À¯Áö¿­.
  • maintenance
    À¯Áö
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blanket mass treatment
    Àü¿øÁý´ÜÄ¡·á¹ý
  • mass treatment
    Áý´ÜÄ¡·á
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Briggs-Haldane treatment
    ºê¸¯½º-ÇÒµ§ ó¸®(ô¥×â)
  • Michaelis-Menten treatment
    ¹ÌŰ¿¤¸®½º-¸àÅ٠ó¸®(ô¥×â)
  • agonist
    ÀÛµ¿Ã¼ (íÂÔÑô÷)
  • cholinergic agonist
    Äݸ°ÀÛµ¿Á¦(íÂÔÑð¥)
  • partial agonist
    ºÎºÐ ÀÛµ¿Á¦(Ý»ÝÂíÂÔÑð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • maintenance
    À¯Áö
  • maintenance dose
    À¯Áö¿ë·®
  • maintenance therapy
    À¯Áö¿ë¹ý
  • local treatment
    ±¹¼ÒÄ¡·á, ±¹¼Ò¿ä¹ý
  • palliative treatment
    °í½ÄÀûÄ¡·á
  • radical treatment
    ±ÙÄ¡¿ä¹ý
  • supportive treatment
    ÁöÁö¿ä¹ý
  • surgical treatment
    ¿Ü°ú¿ä¹ý
  • treatment
    Ä¡·á, ¿ä¹ý, ó¸®, óġ
  • treatment of choice
    ÃÖÀû¿ä¹ý
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IHSS(= HCMP) Idiopathic Hypertrophic Subaortic Stenosis
  = Obstructive Idiopathic Hypertrophic Car...
ORA opiate receptor agonist
PAA partial agonist activity; phenylacetic acid; phosphonoacetic acid; physical abilities analysis; plas...
MMATP methadone maintenance and aftercare treatment program
MMTP methadone maintenance treatment program
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MMT Methadone Maintenance Treatment
MMTP Methadone Maintenance Treatment Program
R,S receptor agonist
8-OH-DPAT 5-HT agonist 8-hydroxy-2-(di-n-propylamino) tetralin
8-OH-DPAT 5-HT(1A) receptor agonist, 8-hydroxy 2(di-n-propyl(amino)tetralin
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • average maintenance dose
    µð±âÅ»¸®½º Æò±Õ À¯Áö·®
  • health maintenance organization
    °Ç°­ À¯Áö Á¶Á÷
    ¹Ì¸® ÀÏÁ¤¾×À» Á¤±âÀûÀ¸·Î ¼±ºÒÇϸé, ½ÇÁ¦ Áø·á¸¦ ¹ÞÀº ¾ç¿¡ °ü°è¾øÀÌ ¿¹¹æÀ» Æ÷ÇÔÇÑ ÃѰýÀûÀÎ ÀÇ·á ¼­ºñ½º¸¦ ÇØÁÖ´Â Á¶Á÷À¸·Î¼­, ÀÓÀÇ·Î °¡ÀÔÇÏ´Â ÀÏÁ¾ÀÇ ¼±ºÒÁ¦ ÀǷẸÇèÀÌ´Ù.
  • heat of maintenance
    À¯Áö ¿­
  • maintenance dose
    À¯Áö·®, À¯Áö ¿ë·®
    ÀÏÁ¤ÇÑ »óŸ¦ À¯ÁöÇϱâ À§Çؼ­ ÇÊ¿äÇÑ ¾àÁ¦ÀÇ Åõ¿©·®.
  • maintenance of denture
    ÀÇÄ¡ º¸Á¸
    ÀÇÄ¡¸¦ »ðÀÔÇÑ ÈÄ¿¡ ÀÇÄ¡¿¡ ´ëÇÑ °ü½É°ú óÁöÀε¥ º¸Ã¶¹° ÀåÂø¿¡ À־ Áß¿äÇÑ ºñÁßÀ» Â÷ÁöÇϰí, ÇÑÁ¤ÁöÀ» ¼ö´Â ¾øÀ¸³ª ÀÇÄ¡ÀÇ ¼ö¸í°úµµ °ü°è°¡ ±í´Ù.
  • 2-adrenergic agonist
    2-¾Æµå·¹³¯¸° ÀÛ¿ëÁ¦, 2-¾Æµå·¹³¯¸° ÀÛµ¿Á¦
  • adrenergic agonist
    ¾Æµå·¹³¯¸°¼º ÀÛµ¿¾à
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü¸¦ ÈïºÐ½ÃÅ´À¸·Î½á È¿°ú¸¦ ³ªÅ¸³»´Â ¾à¹°. ´ë°Ô ¾Æ¹Î È­ÇÕ¹°À̹ǷΠ±³°¨½Å°æ À¯»ç ¾Æ¹ÎÀ̶ó°íµµ ÇÑ´Ù.
  • agonist muscle
    µ¿±Ù±º, ÁÖµ¿±Ù
  • alpha 2 agonist clonidine
    ¾ËÆÄ 2 ÀÛµ¿ Ŭ·Î´Ïµò
  • dopamine autoreceptor agonist
    µµÆÄ¹Î ÀÚ°¡ ¼ö¿ëü È¿ÇöÁ¦
  • high-affinity agonist
    °íģȭ¼º ÀÛ¿ë ¹°Áú
  • opiate agonist alkaloid
    ¾ÆÆí¼º ÀÛµ¿ ¹°Áú ¾ËÄ«·ÎÀ̵å
  • abortive treatment
    ºÎÀü ¿ä¹ý
    °¨¿° Á÷ÈÄ
  • age treatment
    ½ÃÈ¿ ó¸®
    ½ÃÈ¿ °æÈ­¸¦ ´Ü½Ã°£¿¡ ÀÏÀ¸Å°±â À§ÇØ °¡¿­ÇÏ´Â ¿­ ó¸®.
  • Bargen's treatment
    ¹Ù¸£°Õ
    Ç÷û¿¡ ÀÇÇÑ ´ëÀå¿°ÀÇ ¿ä¹ý.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
maintenance treatment Treatment given for a period of months or years to maintain remission and eliminate any residual leukaemic cells in the body, usually for acute lymphoblastic leukaemia.
(13 Nov 1997)
agonist 1. <anatomy> A prime mover.
2. <pharmacology> A drug that has affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances, thus triggering a biochemical response.
(18 Nov 1997)
calcium channel agonist <pharmacology> Agents that increase calcium influx into calcium channels of excitable tissues.
This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture.
(12 Dec 1998)
receptor agonist A substance that mimics a specificneurotransmitter, is able to attach to that neurotransmitter's receptor and thereby produces the same action that theneurotransmitter usually produces. Drugs are often designed as receptor agonists to treat a variety of diseases and disorders whenthe original chemical substance is missing or depleted.
(22 May 1997)
mixed opioid agonist-antagonist <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type.
(13 Nov 1997)
muscarinic agonist Drugs that bind to and activate muscarinic cholinergic receptors (receptors, muscarinic). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate.
(12 Dec 1998)
histamine agonist Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically.
(12 Dec 1998)
opioid agonist <pharmacology> Any morphine-like compound that produces bodily effects including pain relief, sedation, constipation and respiratory depression.
(16 Dec 1997)
opioid partial agonist <pharmacology> A compound that has an affinity for and stimulates physiologic activity at the same cell receptors as opioid agonists but that produces only a partial (i.e., submaximal) bodily response.
(16 Dec 1997)
LH and RH agonist <pharmacology> Particular medications that act as potent inhibitors of gonadotrophin (testosterone) secretion. They act to inhibit the production of testosterone through a feedback mechanism on the pituitary gland. LH and RH agonists are useful in the treatment of prostate cancer.
(14 Oct 1997)
air quality maintenance area Specific populated area where air quality is a problem for one or more pollutants (Portland-Vancouver, Salem, Eugene-Springfield, Medford-Ashland).
(05 Dec 1998)
maintenance The upkeep of property or equipment.
(12 Dec 1998)
maintenance and engineering, hospital Hospital department whose primary function is the upkeep and supervision of the buildings and grounds and the maintenance of hospital physical plant and equipment which requires engineering expertise.
(12 Dec 1998)
maintenance dose In chemotherapy, systematic dosage at a level that maintains protection against exacerbation.
(05 Mar 2000)
maintenance drug therapy In chemotherapy, systematic dosage at a level that maintains protection against exacerbation.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agonist
    ½Î¿ò(°æ±â)ÀÇ °¡´ãÀÚ;(¹®ÇÐ ÀÛǰÀÇ)ÁÖÀΰø;ÁÖµ¿(ÀÛµ¿)±Ù;ÀÛ¿ë(ÀÛµ¿)¾à(¹°Áú)
  • treatment
    Ãë±Þ
  • Pasteur treatment
    ±¤°ßº´ ¿¹¹æ Á¢Á¾
  • heat treatment
    ¿­Ã³¸®
  • medical treatment
    (³»°úÀû)Ä¡·á
  • national treatment
    (¿Ü±³)³»±¹¹Î ´ë¿ì
  • pneumothorax treatment
    ±âÈä¼ú
  • preferential treatment
    ¿ì´ë
  • treatment
    ó¸®;°¡°ø;´ë¿ì;´ëÁ¢;(ÀÇ»çÀÇ)Ä¡·á(¹ý);Ä¡·áÁ¦
  • maintenance
    Áö¼ÓÇÏ´Ù,À¯ÁöÇÏ´Ù,ÁöÅÊÇÏ´Ù,º¸Á¸ÇÏ´Ù,ºÎ¾çÇÏ´Ù,ÁÖÀåÇÏ´Ù
  • corrective maintenance
    °íÀå ¼ö¸®
  • income maintenance
    (¹Ì)(Á¤ºÎÁö±Þ)¼Òµæ;º¸Á¶(À¯Áö)±Ý
  • industrial maintenance
    ½Ç¾÷ÀÚ ±¸Á¦Á¦µµ
  • maintenance
    À¯Áö;º¸Á¸;Áö¼Ó;ºÎ¾ç(·á);»ý°è;ÁÖÀå
  • methadone maintenance
    ¸ÞŸµ· À¯Ä¡¹ý(Çì·ÎÀÎ Áßµ¶ µîÀÇ Ä¡·á Áß¿¡ ´ë¿ë ¸¶¾àÀ¸·Î ¸ÞŸµ·À» ÁÜ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á